Biomea Fusion (BMEA) Study result summary

Disease context and unmet need

• Type 1 diabetes affects 9.5 million globally, including 1.8 million in the US, with 513,000 new cases annually worldwide.

• T1D is marked by autoimmune destruction of beta cells, leading to lifelong insulin dependence and severe complications.

• No approved therapies restore endogenous insulin production or address progressive beta cell loss in stage 3 T1D.

• Current treatments focus on immune modulation or beta cell preservation, but none have shown durable restoration outside of cell transplantation.

Biological rationale and preclinical data

• Menin inhibition, as seen in pregnancy and lactation, enables beta cell expansion and increased insulin production.

• Icovamenib, a menin inhibitor, reduced blood glucose in diabetic rat models and promoted beta cell proliferation in human islet studies under hyperglycemic conditions.

• Preclinical studies consistently link reduced menin to improved beta cell mass and function.

Study design and patient population

• COVALENT-112 was an open-label Phase 2 trial enrolling adults with stage 3 T1D, split into cohorts by disease duration (0–3 years and 3–15 years).

• Patients received 100 mg or 200 mg icovamenib daily for 12 weeks, followed by 40 weeks of follow-up.

• Cohort 1: diagnosed <3 years, C-peptide ≥0.2 nmol/L; Cohort 2: diagnosed 3–15 years, C-peptide ≥0.08 nmol/L.

• Enrollment was reduced due to a temporary FDA clinical hold; a planned placebo-controlled part was not completed.